Compare Medtronic PLC (MDT) vs Microsoft (MSFT) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Microsoft (MSFT) trades at $393.82, down 1.82% over the past day, with a bullish technical signal from moving averages and support near $390. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust, reaching $281.72 billion in 2025, and analyst sentiment is overwhelmingly positive with an 80.49% buy rating.

The outlook for MSFT is favorable, driven by AI leadership, cloud momentum, and consistent profitability, though risks include elevated capital expenditure concerns and competitive pressures. The consensus price target of $546.70 implies significant upside, supported by solid cash flow generation and a strong balance sheet.